• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

Key Takeaways

  • The PSORIATYK SCALP trial confirmed deucravacitinib's efficacy in moderate to severe scalp psoriasis, showing significant clinical improvements over placebo.
  • Participants were randomized to deucravacitinib or placebo, with a switch to open-label treatment after 16 weeks for long-term assessment.
SHOW MORE

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

Psoriasis of the scalp
Image Credit: © Ilia

Bristol Myers Squibb presented the results of the phase 3b/4 PSORIATYK SCALP trial at the 2024 Fall Clinical Dermatology Conference. The data, showcased in a poster, highlighted the efficacy and safety of deucravacitinib (Sotyktu) in patients with moderate to severe scalp psoriasis, demonstrating significant improvements in clinical outcomes compared to placebo.

The PSORIATYK SCALP trial was a multicenter, randomized, double-blinded, placebo-controlled study designed to evaluate the efficacy and safety of deucravacitinib in adults aged 18 years and older with moderate to severe scalp psoriasis.

The trial enrolled participants who presented with a scalp-specific Physician Global Assessment (ss-PGA) score of 3 or higher, Psoriasis Scalp Severity Index (PSSI) score of at least 12, and body surface area involvement of 3% or more.

Participants were randomized in a 1:2 ratio to receive either deucravacitinib 6 mg once daily or a placebo. After 16 weeks, all participants were switched to open-label deucravacitinib for an additional 36 weeks, allowing for a comprehensive assessment of long-term efficacy and safety.

The primary endpoint of the study was the proportion of participants achieving an ss-PGA score of 0 or 1, indicating clear or almost clear scalp psoriasis. Key secondary endpoints included the achievement of a 90% improvement in the PSSI score and the assessment of scalp-specific itch using a numeric rating scale.

At the primary endpoint assessment at 16 weeks, a significantly higher percentage of patients receiving deucravacitinib achieved an ss-PGA score of 0 or 1 compared to those on placebo. Additionally, improvements in the PSSI score and reductions in scalp-specific itch were observed, underscoring the treatment's efficacy.

Safety assessments revealed that deucravacitinib was generally well-tolerated, with adverse events comparable to those seen in placebo-treated patients. The most common adverse events included headache and upper respiratory infections, which were consistent with findings from previous studies of TYK2 inhibitors.

"These results support the efficacy and safety of once-daily oral deucravacitinib in patients with moderate to severe scalp psoriasis, including those with less extensive overall body psoriasis," according to poster authors Callis Duffin et al.

For more news from Fall Clinical, subscribe to receive our eNewsletter.

Reference

  1. Callis Duffin K, Egeberg A, Nascimento A, et al. Efficacy and safety of deucravacitinib in patients with moderate to severe scalp psoriasis: results from the PSORIATYK SCALP trial. Presented at: Fall Clinical 2024; October 24-27, 2024; Las Vegas, Nevada.
Related Videos
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
Omar Noor, MD, FAAD, is featured in this series.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
© 2024 MJH Life Sciences

All rights reserved.